🔗 Share this article

While the US undertakes sweeping adjustments to its immunization guidelines, an unexpected name appears unexpectedly: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who rose to prominence by questioning Covid shots throughout the pandemic and has concentrated on alleged deaths after Covid immunization in her short time at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Immunization Program

Health officials were set to reveal major changes to the childhood vaccination calendar in December, aligning the US with Denmark’s immunization schedule, sources say – a major change that would put the US at odds with a large portion of the global community with insufficient data for benefit. The planned update has been postponed until the new year.

In place of the director of the vaccine center, Høeg is listed to speak at the event. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the office this year.

A New Direction at the Agency

The acting appointment could signify a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Prasad consolidate power at the regulatory agency – and it suggests a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

Dr. Høeg has frequently advocated for halting some pediatric shot schedules in the US so as to align more in line with Denmark, a society with comprehensive healthcare and a citizenry about the population of Wisconsin’s.

So far comments, she has continued to focus on vaccination policy – usually the domain of Prasad, chief of the FDA’s CBER – instead of pharmaceutical oversight.

Questions Over Qualifications

The appointee has no obvious background in pharmaceutical research, oversight or management, which has been customary for former leaders of the CBER. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since spring.

“She appears not to have the necessary background” for overseeing the CDER, remarked Jonathan Howard. “She has not conducted a scientific study. She is not versed in leading a sizeable institution. She has no expertise in drug approvals.”

Previous heads of the center would “understand legal statutes and the science of drug development”, commented Dr. Janet Woodcock. “Objectively, she doesn’t have the kind of background that former directors who led the center have had.”

CDER has an enormous workload at the FDA, she pointed out.

“The public just pays attention on the new drug program, but the generic program authorizes thousands of generic medications. There’s a biosimilars division, OTC medication office and other areas, and each of these have to be managed,” she said. “The area you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a major management component to the position, which oversees in excess of 5,000 staff members. “It is a massive leadership role, if you perform it correctly,” she said.

Agency Reaction and Disputed Policies

In response to concerns about Dr. Høeg's qualifications and whether this appointment signifies more teamwork among agency officials on immunizations, a press secretary said that the “inquiries stem from incorrect premises”.

“Her experience matches the responsibilities of her position,” the representative stated, noting the period Dr. Høeg spent counseling the agency head on “drug safety and approval science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Dr. Høeg assumes responsibility for the commissioner’s recently launched fast-track approval initiative, a controversial one-day therapy clearance system that apparently concerned her preceding directors. “How are these drugs being chosen for this voucher program? Who makes the calls?” Dr. Howard asked. “There is a lot of secrecy occurring at the FDA right now.”

In general, he stated, “the FDA seems to be moving towards laxer regulations of all drugs, with the exception of immunizations.”

Documented Track Record on Immunizations

Concerning vaccines, Dr. Høeg has a clearer, if troubling, track record, critics said. She authored a study using unconfirmed volunteer-provided data to estimate the frequency of myocarditis after Covid vaccination. She counseled the Florida top health official Dr. Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccines are more dangerous than they are.

Among her “wish list” for the incoming administration featured changing rules for novel immunizations and halting “optional” immunizations, she stated post-election on a online show. At the agency, Høeg has reportedly suggested excluding young men from obtaining Covid vaccines.

“She is an complete dogmatist who commences with her conclusions and reverse-engineers to retrofit the evidence in a very misleading, fraudulent fashion,” Howard argued.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined other contrarians, {like|